Cluster classification of a Brazilian gastric cancer cohort reveals remarkable populational differences in normal p53 rate

被引:0
作者
Queiroz, Fabio Ribeiro [1 ]
Braga, Leticia da Conceicao [1 ]
Melo, Carolina Pereira de Souza [1 ]
Gomes, Matheus de Souza [2 ]
do Amaral, Laurence Rodrigues [2 ]
Salles, Paulo Guilherme de Oliveira [1 ]
机构
[1] Inst Mario Penna, Belo Horizonte, MG, Brazil
[2] Univ Fed Uberlandia, Lab Bioinformat & Anal Mol, Patos De Minas, MG, Brazil
来源
EINSTEIN-SAO PAULO | 2024年 / 22卷
关键词
Gastric neoplasms; Cluster analysis; Genetic heterogeneity; Genes; p53; Immunohistochemistry; Adenocarcinoma; Biomarkers; EXPRESSION-BASED CLASSIFICATION; GASTROESOPHAGEAL JUNCTION; PLUS CHEMOTHERAPY; ESOPHAGEAL; SUBTYPES; CARCINOMA; NIVOLUMAB; PROTEIN; JAPAN;
D O I
10.31744/einstein_journal/2024AO0508
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Gastric adenocarcinoma remains an aggressive disease with a poor prognosis, as evidenced by a 5-year survival rate of approximately 31%. The histological classifications already proposed do not accurately reflect the high biological heterogeneity of this neoplasm, particularly in diverse populations, and new classification systems using genetic markers have recently been proposed. Following these newly proposed models, we aimed to assess the cluster distribution in a Brazilian cohort. Furthermore, we evaluated whether the inclusion of other clinical and histological parameters could enhance the predictive value. Methods: We used a previously described four-immunohistochemistry/EBER-ISH marker to classify a cohort of 30 Brazilian patients with gastric adenocarcinoma into five different clusters and compared the distribution with other genetically diverse populations. Furthermore, we used artificial intelligence methods to evaluate whether other clinical and pathological parameters could improve the results of the methodology. Results: Disclosing the genetic variability between populations, we observed a more balanced distribution of the aberrant/normal p53 ratio (0.6) between patients negative for the other markers tested, unlike previous studies with Asian and North American populations. In addition, decision tree analysis reinforced the efficiency of these new classifications, as the stratification accuracy was not altered with or without additional data. Conclusion: Our study underscores the importance of local research in characterizing diverse populations and highlights the complementary role of molecular biomarkers in personalized medicine for gastric adenocarcinoma, enhancing diagnostic accuracy and potentially improving survival rates.
引用
收藏
页数:8
相关论文
共 29 条
[1]   High-throughput Protein and mRNA Expression-based Classification of Gastric Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications [J].
Ahn, Sangjeong ;
Lee, So-Jeong ;
Kim, Yonugkeum ;
Kim, Ahrong ;
Shin, Nari ;
Choi, Kyung Un ;
Lee, Chang-Hun ;
Huh, Gi Yeong ;
Kim, Kyong-Mee ;
Setia, Namrata ;
Lauwers, Gregory Y. ;
Park, Do Youn .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2017, 41 (01) :106-115
[2]   Comprehensive molecular characterization of gastric adenocarcinoma [J].
Bass, Adam J. ;
Thorsson, Vesteinn ;
Shmulevich, Ilya ;
Reynolds, Sheila M. ;
Miller, Michael ;
Bernard, Brady ;
Hinoue, Toshinori ;
Laird, Peter W. ;
Curtis, Christina ;
Shen, Hui ;
Weisenberger, Daniel J. ;
Schultz, Nikolaus ;
Shen, Ronglai ;
Weinhold, Nils ;
Keiser, David P. ;
Bowlby, Reanne ;
Sipahimalani, Payal ;
Cherniack, Andrew D. ;
Getz, Gad ;
Liu, Yingchun ;
Noble, Michael S. ;
Pedamallu, Chandra ;
Sougnez, Carrie ;
Taylor-Weiner, Amaro ;
Akbani, Rehan ;
Lee, Ju-Seog ;
Liu, Wenbin ;
Mills, Gordon B. ;
Yang, Da ;
Zhang, Wei ;
Pantazi, Angeliki ;
Parfenov, Michael ;
Gulley, Margaret ;
Piazuelo, M. Blanca ;
Schneider, Barbara G. ;
Kim, Jihun ;
Boussioutas, Alex ;
Sheth, Margi ;
Demchok, John A. ;
Rabkin, Charles S. ;
Willis, Joseph E. ;
Ng, Sam ;
Garman, Katherine ;
Beer, David G. ;
Pennathur, Arjun ;
Raphael, Benjamin J. ;
Wu, Hsin-Ta ;
Odze, Robert ;
Kim, Hark K. ;
Bowen, Jay .
NATURE, 2014, 513 (7517) :202-209
[3]   PD-L1 is an independent prognostic predictor in gastric cancer of Western patients [J].
Boeger, Christine ;
Behrens, Hans-Michael ;
Mathiak, Micaela ;
Krueger, Sandra ;
Kalthoff, Holger ;
Roecken, Christoph .
ONCOTARGET, 2016, 7 (17) :24269-24283
[4]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[5]   PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score [J].
Cho, Yoon Ah ;
Lee, Hyunwoo ;
Kim, Deok Geun ;
Kim, Hyunjin ;
Ha, Sang Yun ;
Yoon-La Choi ;
Jang, Kee-Taek ;
Kim, Kyoung-Mee .
CANCERS, 2021, 13 (18)
[6]   Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes [J].
Cristescu, Razvan ;
Lee, Jeeyun ;
Nebozhyn, Michael ;
Kim, Kyoung-Mee ;
Ting, Jason C. ;
Wong, Swee Seong ;
Liu, Jiangang ;
Yue, Yong Gang ;
Wang, Jian ;
Yu, Kun ;
Ye, Xiang S. ;
Do, In-Gu ;
Liu, Shawn ;
Gong, Lara ;
Fu, Jake ;
Jin, Jason Gang ;
Choi, Min Gew ;
Sohn, Tae Sung ;
Lee, Joon Ho ;
Bae, Jae Moon ;
Kim, Seung Tae ;
Park, Se Hoon ;
Sohn, Insuk ;
Jung, Sin-Ho ;
Tan, Patrick ;
Chen, Ronghua ;
Hardwick, James ;
Kang, Won Ki ;
Ayers, Mark ;
Dai Hongyue ;
Reinhard, Christoph ;
Loboda, Andrey ;
Kim, Sung ;
Aggarwal, Amit .
NATURE MEDICINE, 2015, 21 (05) :449-U217
[7]   The difference in gastric cancer between Japan, USA and Europe: What are the facts? What are the suggestions? [J].
Davis, PA ;
Sano, T .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 40 (01) :77-94
[8]   Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods [J].
Ferlay, J. ;
Colombet, M. ;
Soerjomataram, I. ;
Mathers, C. ;
Parkin, D. M. ;
Pineros, M. ;
Znaor, A. ;
Bray, F. .
INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (08) :1941-1953
[9]  
Ferlay J E.M., 2020, Global Cancer Observatory: Cancer Today
[10]   First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial [J].
Janjigian, Yelena Y. ;
Shitara, Kohei ;
Moehler, Markus ;
Garrido, Marcelo ;
Salman, Pamela ;
Shen, Lin ;
Wyrwicz, Lucjan ;
Yamaguchi, Kensei ;
Skoczylas, Tomasz ;
Bragagnoli, Arinilda Campos ;
Liu, Tianshu ;
Schenker, Michael ;
Yanez, Patricio ;
Tehfe, Mustapha ;
Kowalyszyn, Ruben ;
Karamouzis, Michalis V. ;
Bruges, Ricardo ;
Zander, Thomas ;
Pazo-Cid, Roberto ;
Hitre, Erika ;
Feeney, Kynan ;
Cleary, James M. ;
Poulart, Valerie ;
Cullen, Dana ;
Lei, Ming ;
Xiao, Hong ;
Kondo, Kaoru ;
Li, Mingshun ;
Ajani, Jaffer A. .
LANCET, 2021, 398 (10294) :27-40